After the clinical implementation of amyloid-β-targeting therapies for people with cognitive impairment due to Alzheimer’s disease (AD), there is an urgent need to efficiently identify this patient ...
In recent years, notable progress has been made in identifying blood-based biomarkers (BBMs) for detecting Alzheimer’s disease (AD) pathology in symptomatic patients 1. Among these BBMs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results